News | June 02, 2021
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
This marks Glenmark's first synthetic decapeptide injectable approval
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Subscribe To Our Newsletter & Stay Updated
